Working... Menu

Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01689376
Expanded Access Status : No longer available
First Posted : September 21, 2012
Last Update Posted : August 16, 2016
Information provided by (Responsible Party):

Brief Summary:
The purpose of this Managed Access Program is to provide regorafenib to patients diagnosed with metastatic and / or unresectable GIST who have progressed after standard therapy.

Condition or disease Intervention/treatment
Gastrointestinal Stromal Tumors Drug: Regorafenib (BAY73-4506)

Detailed Description:
This "Managed Access Program" covers the different types of programs in the participating countries (including compassionate use program, named patient program, cohorts e.g. ATU in France, etc).

Layout table for study information
Study Type : Expanded Access
Official Title: Guidelines for Treatment With Regorafenib in Patients With Gastrointestinal Stromal Tumors (GIST) After Disease Progression on or Intolerance to Imatinib and Sunitinib (Managed Access Program)

Intervention Details:
  • Drug: Regorafenib (BAY73-4506)
    160 mg BAY73-4506, 3 weeks on drug, 1 week off drug

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Signed Informed consent (IC) and data protection clarification obtained before any specific treatment related procedures. Patients or their legal representative must be able to understand and willing to sign a written IC.
  • Male or female patients >= 18 years of age
  • Patients with histologically confirmed metastatic and / or unresectable GIST
  • At least imatinib and sunitinib as prior treatment regimens with progression on or intolerance to imatinib and sunitinib
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of =< 1
  • Adequate bone marrow, liver and renal function
  • Women of childbearing potential and men must agree to use adequate contraception before entering the program until at least 8 weeks after the last regorafenib administration in the program. The treating physician or a designated associate is requested to advise the patient on how to achieve adequate birth control. Adequate contraception is defined in this program as any medically recommend method (or combination of methods) as per standard of care.

Exclusion Criteria:

  • Prior treatment with regorafenib
  • Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to starting regorafenib
  • Pregnant or breast-feeding patients. Women of childbearing potential must have a pregnancy test performed a maximum of 7 days before start of treatment, and a negative result must be documented before start of regorafenib.
  • Congestive heart failure New York Heart Association (NYHA) class 2
  • Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months)
  • Myocardial infarction less than 6 months before start of regorafenib
  • Cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted)
  • Uncontrolled hypertension. (Systolic blood pressure > 140 mmHg or diastolic pressure > 90 mmHg despite optimal medical management)
  • Pleural effusion or ascites that causes respiratory compromise (National Cancer Institute's common terminology criteria for adverse events [NCI-CTCAE] v.4.0 Grade >= 2 dyspnea)
  • Ongoing infection NCI-CTCAE v.4.0 Grade > 2
  • Known history of human immunodeficiency virus (HIV) infection
  • Active hepatitis B or C, or chronic hepatitis B or C requiring treatment with antiviral therapy
  • Patients with seizure disorder requiring medication
  • History of organ allograft
  • Patients with evidence or history of any bleeding diathesis, irrespective of severity
  • Any hemorrhage or bleeding event NCI-CTCAE v. 4.0 Grade >= 3 within 4 weeks prior to the start of regorafenib
  • Non-healing wound, ulcer, or bone fracture
  • Renal failure requiring hemo- or peritoneal dialysis
  • Dehydration NCI-CTCAE v.4.0 Grade >= 1
  • Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the program
  • Known hypersensitivity to regorafenib, the drug class, or excipients in the formulation
  • Any illness or medical conditions that are unstable or could jeopardize the safety of the patient and his / her compliance in the program
  • Interstitial lung disease with ongoing signs and symptoms
  • Persistent proteinuria of NCI-CTCAE v.4.0 Grade 3 (> 3.5 g/24 hours)
  • Patients unable to swallow oral medications
  • Any malabsorption condition
  • Unresolved toxicity higher than NCI-CTCAE v.4.0 Grade 1 (excluding alopecia, anaemia, and hypothyroidism) attributed to any prior therapy / procedure
  • Concomitant participation or participation within the last 30 days in a clinical trial
  • Non-permissible concomitant medications and procedures (systemic anti-cancer therapy including cytotoxic therapy, signal transduction inhibitors, immunotherapy and hormonal therapy or any experimental therapies; Tyrosine Kinase Inhibitors (TKIs); bone marrow transplant or stem cell rescue; use of biologic response modifiers, such as granulocyte colony stimulating factor (G CSF), within 3 weeks prior to entering the program; St John's Wort; grapefruit and grapefruit juice; all traditional medicines with an anti-cancer indication)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01689376

Sponsors and Collaborators
Layout table for investigator information
Study Director: Bayer Study Director Bayer

Layout table for additonal information
Responsible Party: Bayer Identifier: NCT01689376     History of Changes
Other Study ID Numbers: 16040
First Posted: September 21, 2012    Key Record Dates
Last Update Posted: August 16, 2016
Last Verified: August 2016

Additional relevant MeSH terms:
Layout table for MeSH terms
Gastrointestinal Stromal Tumors
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Gastrointestinal Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Gastrointestinal Diseases